Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06423781 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
A Phase 2 study, sponsored by Biohaven Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 233
- Enrollment target
NCT06423781 is a Phase 2 study that has completed, run by Biohaven Therapeutics. The registered enrollment target is 233 participants.
The verdict
NCT06423781, a Phase 2 study, has completed, sponsored by Biohaven Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 233 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).
Interventions
- DRUG BHV-7000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2026-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06423781
The ClinicalTrials.gov registry entry for NCT06423781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BHV-7000 is the first listed.
NCT06423781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06423781 about?
NCT06423781 is a clinical study titled "Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)". The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).
What is the current status of trial NCT06423781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 233 participants. The study started on 2024-08-01. Estimated completion is 2026-03-18.
What interventions are being tested in trial NCT06423781?
The interventions under investigation include: BHV-7000 (DRUG).
Who is sponsoring clinical trial NCT06423781?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.